In a significant move to strengthen epilepsy management in India, Akums Drugs & Pharmaceuticals has highlighted lacosamide, a well-established antiepileptic drug (AED), as a versatile solution that meets the needs of patients across age groups and clinical settings. Available in tablet, syrup, and injectable forms, the drug caters to outpatient, inpatient, and emergency care, offering flexibility that few AEDs provide.

“With lacosamide, we continue our mission to support patient-centric care in neurology,” said Sanjeev Jain, MD, Akums Drugs & Pharmaceuticals. “Its flexible dosing options and multiple formulations address unmet needs in epilepsy management, ensuring continuity of therapy whether at home or in hospital settings. This aligns with our broader CNS portfolio strategy and commitment to improving patient outcomes.”

Clinical research has consistently demonstrated lacosamide’s efficacy and tolerability. Long-term adjunctive studies have shown sustained seizure control for up to five years, while recent findings confirm its safety and effectiveness even in pediatric refractory epilepsy, including children under four years of age. Intravenous formulations have further proven beneficial in acute repetitive seizures and status epilepticus, underscoring the drug’s value in urgent and critical care.

Unlike conventional sodium channel blockers that act on fast inactivation, lacosamide uniquely enhances slow inactivation of voltage-gated sodium channels, stabilizing overactive neurons without disturbing normal brain function. This mechanism translates into fewer cognitive side effects, better tolerability, and a favorable drug–drug interaction profile compared with older antiepileptics.

Experts also note lacosamide’s advantages in patients with complex health profiles. It has shown comparable efficacy to carbamazepine-CR in those with psychiatric comorbidities, long-term safety in post-stroke epilepsy patients on anticoagulants, and positive outcomes in vulnerable groups, including people who inject drugs and pregnant women. Its favorable safety profile compared with alternatives like perampanel strengthens its role as a go-to option in modern epilepsy care.

“Lacosamide has proven to be a reliable option for both adjunctive and monotherapy use,” said Dr. Pooja Anand, Consultant, Neurology, Paras Health, Gurugram. “Its favorable tolerability, combined with flexible administration, improves adherence and minimizes therapy interruptions, which is critical for seizure control and patient quality of life.”

With formulations tailored for individualized therapy—from tablets ranging between 50 mg and 200 mg, to a 15 mg/mL syrup for patients with swallowing difficulties, and a 10 mg/mL injectable for uninterrupted hospital care—lacosamide is addressing a crucial gap in India’s epilepsy treatment landscape.

For Akums, which has long invested in its CNS portfolio, lacosamide represents both a cornerstone and a future-ready solution. At a time when epilepsy continues to affect millions in India and worldwide, its robust clinical backing, wide applicability, and patient-friendly design make it a trusted choice for clinicians and patients alike.